Southern Shuanglin Bio-Pharmacy revises governance, increases capital, removes supervisory board

Southern Shuanglin Bio-Pharmacy held board and supervisory board meetings on December 4, 2025, to approve comprehensive revisions to its articles of association and various governance policies. Key changes include an increase in registered capital from 732,645,729 yuan to 950,397,386 yuan and the removal of the supervisory board, with its functions transferred to the board's audit committee. The company also updated its internal control, risk management, and information disclosure frameworks to align with the new company law and enhance operational efficiency.

The approved revisions encompass a wide range of policies, including significant changes to investment management, related-party transactions, external guarantees, entrusted wealth management, fundraising, and the internal audit system. These updates aim to strengthen governance, protect shareholder interests, and ensure compliance with evolving regulatory requirements, with many requiring shareholder approval at the upcoming December 22, 2025, fourth interim shareholders' meeting.